Gene testing aims to match kids with rare cancers to the right drugs
NCT ID NCT02520713
First seen Apr 30, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This study enrolls children and young adults (up to age 30) with solid tumors that have come back or not responded to standard treatment. Researchers use genetic testing of the tumor to look for specific changes that might point to a targeted therapy. The goal is to see if patients who receive a therapy matched to their tumor's genetic profile live longer than those who do not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02215, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Chicago Comer Children's Hospital
Chicago, Illinois, 60637, United States
-
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75390, United States
-
University of Utah Childrens Medical Center
Salt Lake City, Utah, 84113, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Genetic testing and tumor profiling
What this could lead to
If successful, this could help identify which targeted therapies work best for individual children with hard-to-treat solid tumors, potentially improving survival.
What could go wrong
This is an observational study, not a treatment trial. It may not directly benefit participants, and many patients may not receive a matching therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.